Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8866 to 8880 of 8900 results

  1. 170,000 people in England to have further treatment choice for preventing migraine attacks

    In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England.

  2. New life-extending drug treatment for children and teenagers with an aggressive form of brain cancer

    Dabrafenib with trametinib is a targeted treatment that can be taken at home rather than hospital and improves the length and quality of life for patients..

  3. First treatment to target heart condition set to benefit

    NICE has approved mavacamten, the first treatment that specifically targets a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It means around 7,000 people will now be able to access the treatment on the NHS.

  4. NICE collaborates with international partner agencies to streamline the confidential marking process

    NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and Economic Review changes the way information about health technologies is handled to streamline processes and increase transparency.

  5. 145,000 people in England to have further treatment choice for preventing migraine attacks

    NICE has for the first time recommended an oral treatment for preventing migraines.

  6. NICE recommends olaparib for early breast cancer and metastatic prostate cancer

    Deals for anti-cancer medicine olaparib have paved the way for hundreds to benefit as NICE recommends it for some types of early breast cancer and advanced prostate cancer.

  7. NICE recommends genetic test to prevent newborn babies going deaf

    A genetic test to establish if a newborn baby is vulnerable to deafness if treated with a commonly used antibiotic has been recommended by NICE in final guidance.

  8. 25 years of NICE and focusing on what matters most to deliver for the future

    Home News Podcasts 25 years of NICE and focusing on what matters most to deliver for the future Podcasts 01 May 2024 Listen About this episode

  9. Assessing the familial and genetic risk of ovarian cancer

    Home News Podcasts Assessing the familial and genetic risk of ovarian cancer Podcasts 03 April 2024 Listen About this episode We talk to Ranjit

  10. Learn more about the NICE and NHS England MedTech Pathway consultation

    Home News Podcasts Learn more about the NICE and NHS England MedTech Pathway consultation Podcasts 03 June 2024 Listen About this episode

  11. Learn more about NICE's new guideline on identifying and managing adrenal insufficiency

    Home News Podcasts Learn more about NICE's new guideline on identifying and managing adrenal insufficiency Podcasts 29 August 2024 Listen

  12. NICE to become single point of access for Covid-19 guidance and advice

    NICE announced that it is to host a new, single point of advice on caring for people with Covid-19 and the management of Covid-19 in a variety of clinical settings.

  13. NICE announces start of review of nusinersen Managed Access Agreement

    NICE has today (29 October 2020) announced that it has begun the process to review data collected as part of the Managed Access Agreement (MAA) for nusinersen.

  14. How we can offer a broader range of benefits for people, their families and carers

    NICE has been part of a research project investigating how quality of life measures used to evaluate healthcare treatments such as drugs can be extended into areas of social care and public health.

  15. NICE enables groups and organisations to work together on their response to our online public consultations

    New functionality for online collaboration on consultations, enables groups or organisations to submit a joined-up response.